Compare FRD & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | ALEC |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.2M | 275.8M |
| IPO Year | 1995 | 2019 |
| Metric | FRD | ALEC |
|---|---|---|
| Price | $42.70 | $2.09 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 31.3K | ★ 4.3M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $121,157,278.00 | $21,045,000.00 |
| Revenue This Year | N/A | $214.33 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.84 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $16.55 | $1.09 |
| 52 Week High | $48.77 | $2.76 |
| Indicator | FRD | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 56.68 |
| Support Level | $41.16 | $1.89 |
| Resistance Level | $43.82 | $2.13 |
| Average True Range (ATR) | 1.48 | 0.18 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 69.84 | 79.35 |
Friedman Industries Inc is a manufacturer and processor of metals and operates in two reportable segments: flat-roll products and tubular products. The flat-roll product segment consists of flat-roll processing facilities located in Hickman, Arkansas; Decatur, Alabama; Miami, Florida; East Chicago, Indiana; Granite City, Illinois and Sinton, Texas and a flat-roll distribution facility located in Orlando, Florida. The tubular product segment consists of the Company's Texas Tubular Products division (TTP) located in Lone Star, Texas. TTP operates two electric resistance welded pipe mills with a combined outside diameter (OD). Its products are flat-roll products and tubular products.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.